< Return to Video

The new science of personalized vaccines

  • 0:01 - 0:06
    It is hard to overstate
    the beneficial effects of immunization.
  • 0:07 - 0:10
    According to the US
    Centers for Disease Control,
  • 0:10 - 0:14
    US children born over the last 20 years --
  • 0:14 - 0:19
    for those children, vaccines will prevent
    greater than 322 million illnesses,
  • 0:19 - 0:22
    greater than 21 million hospitalizations,
  • 0:22 - 0:26
    and greater than 730,000 deaths,
  • 0:26 - 0:31
    with the societal cost savings
    of nearly 1.4 trillion dollars.
  • 0:31 - 0:33
    Those are big numbers.
  • 0:33 - 0:35
    But let's zoom in
    and look at a particular example.
  • 0:36 - 0:38
    Vaccines have nearly eliminated
  • 0:38 - 0:42
    a bacterial infection
    called Haemophilus influenzae.
  • 0:42 - 0:45
    This bacterium
    used to infect young infants
  • 0:45 - 0:46
    causing bloodstream infections,
  • 0:46 - 0:49
    pneumonia, meningitis, death
  • 0:49 - 0:51
    or permanent disability.
  • 0:52 - 0:55
    As a young pediatrician,
    I saw a few cases.
  • 0:55 - 0:58
    You folks probably have never
    heard of this disease,
  • 0:58 - 1:01
    because vaccines have been so effective.
  • 1:01 - 1:03
    You could see in the graph on the right
  • 1:03 - 1:05
    that since the introduction of vaccines,
  • 1:05 - 1:08
    the incidence of Haemophilus
    bacterial infections
  • 1:08 - 1:11
    has plummeted like a rock,
    and it's nearly vanished.
  • 1:12 - 1:15
    So vaccines are generally a success story.
  • 1:15 - 1:17
    But we also face challenges.
  • 1:17 - 1:21
    For one, for most vaccines,
    we need to give multiple doses
  • 1:21 - 1:24
    to achieve or maintain protection.
  • 1:25 - 1:29
    The scientific community is working
    on developing single-shot vaccines.
  • 1:29 - 1:33
    Imagine being able to get only one
    influenza shot your whole life,
  • 1:33 - 1:36
    and not having to get
    a seasonal flu vaccine.
  • 1:36 - 1:40
    Certain microbes
    are difficult to immunize against.
  • 1:40 - 1:44
    A classic example is human
    immunodeficiency virus, or HIV.
  • 1:44 - 1:47
    The need is urgent,
    progress is being made;
  • 1:47 - 1:49
    we're not there yet.
  • 1:50 - 1:53
    Another critical element
    in vaccine research right now
  • 1:53 - 1:57
    is optimizing vaccines
    for the most vulnerable among us,
  • 1:57 - 1:59
    the very young and the elderly.
  • 1:59 - 2:01
    And this is an active area of research.
  • 2:02 - 2:06
    Finally, one of the biggest challenges
    we unfortunately face right now
  • 2:06 - 2:08
    are anti-vax attitudes.
  • 2:09 - 2:15
    In fact, it's alarming that over 100,000
    infants and children in the United States
  • 2:15 - 2:17
    have not received any vaccines,
  • 2:17 - 2:19
    and that number is growing.
  • 2:19 - 2:23
    In fact, the World Health
    Organization, or WHO,
  • 2:23 - 2:25
    has declared anti-vax attitudes
  • 2:25 - 2:29
    as one of the 10 most important
    threats to human health
  • 2:29 - 2:31
    in the world today.
  • 2:31 - 2:35
    This graphic illustrates
    the spread of anti-vax sentiment
  • 2:35 - 2:37
    in the state of California,
  • 2:37 - 2:40
    from the year 2000 to 2013,
  • 2:40 - 2:44
    by looking at the percentage
    of public kindergarten students
  • 2:44 - 2:48
    who claim the personal exemption
    against immunization.
  • 2:48 - 2:51
    Anti-vax sentiment is on the rise,
  • 2:51 - 2:53
    and it has very real consequences.
  • 2:53 - 2:55
    Many of you may be aware of the fact
  • 2:55 - 2:59
    that we're seeing infections
    that we thought we conquered long ago
  • 2:59 - 3:00
    coming back.
  • 3:00 - 3:03
    Measles outbreaks have been reported
    in multiple US states.
  • 3:03 - 3:05
    And many have forgotten,
  • 3:05 - 3:08
    but measles is very
    infectious and dangerous.
  • 3:08 - 3:12
    Just a few viral particles
    can infect an individual.
  • 3:13 - 3:15
    And there have been even reports
  • 3:15 - 3:17
    at sporting events
    and at an Olympic stadium
  • 3:17 - 3:20
    where the virus, through the air,
    travels long distances
  • 3:20 - 3:23
    and infects a vulnerable
    person in the crowd.
  • 3:23 - 3:25
    In fact, if I had
    a measles cough right now,
  • 3:25 - 3:27
    (Coughs)
  • 3:27 - 3:31
    somebody in the back
    of this auditorium could get infected.
  • 3:32 - 3:35
    And this has had
    very real-world consequences.
  • 3:35 - 3:36
    Just a few months ago,
  • 3:37 - 3:40
    an airline stewardess
    contracted measles on a flight,
  • 3:40 - 3:43
    the virus entered her brain
    and caused encephalitis,
  • 3:43 - 3:45
    and she died.
  • 3:45 - 3:48
    So people are now dying
    due to this anti-vax sentiment.
  • 3:49 - 3:51
    I do want to take a few minutes
  • 3:51 - 3:53
    to address those
    who don't believe in vaccines
  • 3:53 - 3:55
    and who resist vaccines.
  • 3:56 - 4:01
    As a pediatrician who receives
    my yearly flu vaccination,
  • 4:01 - 4:03
    as a parent of three children
  • 4:03 - 4:08
    who have been vaccinated according
    to the recommended schedule,
  • 4:08 - 4:10
    and as a pediatric infectious
    disease consultant
  • 4:10 - 4:13
    who has taken care
    of young children with meningitis
  • 4:13 - 4:17
    that would have been preventable
    had their parents accepted immunization,
  • 4:17 - 4:19
    this is a personal matter to me.
  • 4:19 - 4:22
    Let's take a look
    at who is going to pay the price
  • 4:22 - 4:26
    if we start dialing back the amount
    of vaccination in our society.
  • 4:27 - 4:29
    This graph depicts, on the Y axis,
  • 4:29 - 4:33
    the number of individuals
    dying of infection in the world.
  • 4:33 - 4:34
    And on the X axis,
  • 4:34 - 4:37
    the age of the individuals who are dying.
  • 4:37 - 4:40
    And as you can see,
    it's very much a U-shaped distribution,
  • 4:40 - 4:43
    and it's particularly stark
    in the very young ages.
  • 4:44 - 4:48
    So vaccines shield
    the very young from infection.
  • 4:49 - 4:52
    And if we want to talk, my friends,
    about what vaccines cause,
  • 4:52 - 4:53
    because there's a lot of speculation,
  • 4:53 - 4:57
    unfounded speculation on the internet,
    of what vaccines cause,
  • 4:57 - 5:01
    vaccines cause adults, OK?
  • 5:01 - 5:02
    That's what they cause.
  • 5:02 - 5:07
    And the other thing that they cause
    is for elderly individuals to live longer.
  • 5:07 - 5:09
    Because they are shielded
    against influenza
  • 5:09 - 5:11
    and other killers of the elderly.
  • 5:12 - 5:14
    Now, let's talk a little bit
  • 5:14 - 5:16
    about how we can improve
    vaccines even further.
  • 5:16 - 5:21
    We can create vaccines that can immunize
    the most vulnerable among us,
  • 5:21 - 5:24
    and perhaps even vaccines
    that protect with single shots.
  • 5:24 - 5:27
    Let me go over a little bit
    of the immunology.
  • 5:27 - 5:30
    In the top panel, what you see
    is a simple vaccine.
  • 5:30 - 5:33
    All vaccines contain
    something called an antigen.
  • 5:33 - 5:36
    The antigen is like a piece
    of a germ, of a microbe,
  • 5:37 - 5:38
    that your body remembers, right?
  • 5:38 - 5:42
    It forms antibodies
    and those antibodies can protect you.
  • 5:42 - 5:45
    So those kind of vaccines
    can induce an immune response,
  • 5:45 - 5:47
    but as you see here,
  • 5:47 - 5:50
    that immune response
    tends to go up and back down,
  • 5:50 - 5:52
    and you need to get another dose
    and another dose
  • 5:52 - 5:54
    to maintain protection.
  • 5:54 - 5:55
    What can we do?
  • 5:56 - 5:58
    We and other scientists around the world
  • 5:58 - 6:01
    are finding molecules
    that can boost a vaccine response.
  • 6:01 - 6:03
    Those are called adjuvants,
  • 6:03 - 6:06
    from the Latin "adjuvare," to help or aid.
  • 6:06 - 6:09
    Adjuvants are molecules
    we might add to a vaccine
  • 6:09 - 6:11
    to get a stronger response.
  • 6:11 - 6:14
    And in the presence of the adjuvant,
    depicted here in red,
  • 6:14 - 6:18
    you have a much more profound
    activation of the white blood cells
  • 6:18 - 6:19
    of your immune system,
  • 6:19 - 6:22
    and generate a much more
    profound immune response,
  • 6:22 - 6:25
    with much higher antibody
    levels, more rapidly,
  • 6:25 - 6:28
    and that lasts a long time
    for durable immunity.
  • 6:28 - 6:32
    Interestingly, these adjuvants
    have different effects
  • 6:32 - 6:35
    depending on the age or other demographic
    factors of the individual.
  • 6:36 - 6:39
    Which brings me to the notion
    of precision vaccines.
  • 6:39 - 6:43
    This is the idea that we will take
    precision medicine --
  • 6:43 - 6:45
    you know what precision
    medicine is, right,
  • 6:45 - 6:48
    that's the idea that populations may vary
  • 6:48 - 6:50
    in their response
    to a particular medicine --
  • 6:50 - 6:52
    and apply that to vaccines.
  • 6:53 - 6:54
    Right?
  • 6:54 - 6:56
    And here in Boston Children's Hospital
  • 6:56 - 6:59
    at the Precision Vaccines
    Program I direct,
  • 6:59 - 7:02
    we have five approaches,
    stepwise approaches we take,
  • 7:02 - 7:04
    to build precision vaccines
  • 7:04 - 7:06
    that are tailored
    to vulnerable populations.
  • 7:06 - 7:08
    Number one,
  • 7:08 - 7:11
    we need to understand
    what the attitude of a given population is
  • 7:11 - 7:12
    towards a vaccine.
  • 7:12 - 7:15
    You could build the most
    sophisticated vaccine in the world,
  • 7:15 - 7:17
    but if nobody wants to take it,
    you're going nowhere.
  • 7:18 - 7:19
    Number two,
  • 7:19 - 7:21
    we have to think
    of the route of immunization.
  • 7:21 - 7:24
    Most vaccines are intramuscular, or IM,
  • 7:24 - 7:27
    but there are others,
    intranasal, oral and others.
  • 7:28 - 7:31
    Then, as I just described to you,
    vaccines have components.
  • 7:31 - 7:33
    All vaccines have an antigen,
  • 7:33 - 7:36
    that's the part of the microbe
    that your body remembers,
  • 7:36 - 7:40
    that you might make antibodies
    or cell-mediated immunity against.
  • 7:40 - 7:42
    And we might add an adjuvant,
    as we talked about,
  • 7:42 - 7:44
    to boost an immune response.
  • 7:44 - 7:45
    But guess what?
  • 7:45 - 7:47
    There are many different
    antigens to choose from,
  • 7:47 - 7:49
    and many different adjuvants.
  • 7:49 - 7:51
    How are we going to make that decision?
  • 7:51 - 7:53
    And the menu of these keeps growing.
  • 7:53 - 7:54
    So on our team,
  • 7:54 - 7:58
    we've developed ways
    to test vaccines outside the body --
  • 7:58 - 7:59
    in Latin, that's "in vitro" --
  • 7:59 - 8:01
    in a tissue culture dish.
  • 8:01 - 8:04
    So we use tissue engineering
    with blood cells
  • 8:04 - 8:06
    to immunize outside the body,
  • 8:06 - 8:08
    and study the effect of the vaccine
  • 8:08 - 8:13
    against, for example, infants
    or elderly individuals or others.
  • 8:13 - 8:16
    And if you think about it,
    this is critical,
  • 8:16 - 8:19
    because if you look at all the infections
    we want to build vaccines against,
  • 8:19 - 8:23
    like Zika virus and Ebola virus
    and HIV and others,
  • 8:23 - 8:25
    all the candidate antigens,
  • 8:25 - 8:27
    all the candidate adjuvants,
  • 8:27 - 8:29
    all the different populations,
  • 8:29 - 8:33
    it's going to be impossible to do
    large, phase III clinical trials
  • 8:33 - 8:34
    for every combination.
  • 8:34 - 8:39
    This is where we think being able
    to test vaccines outside the body
  • 8:39 - 8:42
    can make a big difference
    to accelerate vaccine development.
  • 8:42 - 8:45
    And finally, this whole effort
    is to drive an immune response
  • 8:45 - 8:49
    that will protect against
    that particular pathogen,
  • 8:49 - 8:53
    getting antibodies and other cells
    to defend the body.
  • 8:53 - 8:56
    We are also using additional
    innovative approaches
  • 8:56 - 8:59
    to bring the most cutting-edge science
    to vaccine development.
  • 8:59 - 9:03
    We're taking a deeper dive
    as to how current vaccines protect.
  • 9:03 - 9:06
    We've formed an international consortium
  • 9:06 - 9:10
    to study how hepatitis B vaccine
    protects newborns
  • 9:10 - 9:12
    from hepatitis B infection.
  • 9:12 - 9:13
    And to do this,
  • 9:13 - 9:16
    we've developed a technique
    called small sample, big data.
  • 9:16 - 9:20
    We can get a tiny little drop
    of baby blood before immunization,
  • 9:20 - 9:23
    and take a tiny little drop
    after immunization,
  • 9:23 - 9:26
    and we can measure the inventory
    of all the cells,
  • 9:26 - 9:30
    and all the genes and all the molecules
    in that drop of blood,
  • 9:30 - 9:32
    and we can compare after the vaccine
  • 9:32 - 9:34
    to before the vaccine in that same baby,
  • 9:34 - 9:36
    and understand in a deep way
  • 9:36 - 9:39
    exactly how that successful
    vaccine protects.
  • 9:40 - 9:45
    And those lessons we can use
    to build the next vaccines in the future.
  • 9:45 - 9:48
    So this diagram is really illustrating
    a tiny drop of blood
  • 9:48 - 9:50
    yielding huge amounts of information,
  • 9:50 - 9:52
    tens of thousands of analytes,
  • 9:52 - 9:57
    and that hairball is meant to depict
    the gene pathways that are turned on
  • 9:57 - 9:59
    and the molecular pathways
    that are turned on.
  • 9:59 - 10:02
    So much more to come on that,
    and very exciting science.
  • 10:03 - 10:06
    So we are partnering
    with scientists around the world
  • 10:06 - 10:10
    to bring all these new technologies
    to invigorate vaccine development
  • 10:10 - 10:12
    in a Precision Vaccines Network.
  • 10:12 - 10:14
    We are going to advance
    personalized vaccines
  • 10:14 - 10:17
    for vulnerable populations
    around the world.
  • 10:17 - 10:22
    Our team includes scientists,
    technical experts and physicians.
  • 10:22 - 10:25
    And we're developing vaccines
    against infectious diseases
  • 10:25 - 10:27
    like pertussis, which is whooping cough.
  • 10:27 - 10:29
    We have a whooping cough vaccine,
  • 10:29 - 10:31
    but it requires multiple doses
  • 10:31 - 10:33
    and the immunity keeps dropping.
  • 10:33 - 10:35
    We want to develop a single-shot
    pertussis vaccine.
  • 10:35 - 10:38
    We're working on a vaccine
    for respiratory syncytial virus,
  • 10:38 - 10:42
    the number one cause of infant
    hospitalization in the United States.
  • 10:42 - 10:45
    A better vaccine against influenza,
  • 10:45 - 10:47
    and, of course, HIV.
  • 10:47 - 10:51
    We're also looking at vaccines
    against cancer, allergy,
  • 10:51 - 10:55
    and interestingly, opioid overdose.
  • 10:56 - 10:59
    So, this is my final message to you.
  • 10:59 - 11:02
    Vaccines protect you and your loved ones
  • 11:02 - 11:04
    and the people around you.
  • 11:04 - 11:06
    Not only do they protect you
    against infection,
  • 11:06 - 11:08
    they prevent you
    from spreading it to others.
  • 11:08 - 11:10
    Get immunized.
  • 11:10 - 11:13
    Scientific progress is fragile
    and can be lost.
  • 11:13 - 11:17
    We must foster accurate
    and respectful public dialogue.
  • 11:17 - 11:20
    And finally, we're on the verge
    of great things,
  • 11:20 - 11:22
    a new era of vaccination.
  • 11:22 - 11:25
    We've just scratched the surface
    of what can be accomplished.
  • 11:25 - 11:27
    Please advocate for this research.
  • 11:27 - 11:28
    Thank you.
  • 11:28 - 11:31
    (Applause)
Title:
The new science of personalized vaccines
Speaker:
Ofer Levy
Description:

more » « less
Video Language:
English
Team:
closed TED
Project:
TEDTalks
Duration:
11:44

English subtitles

Revisions Compare revisions